Form 4: Surrozen Director Acquires Options in Latest SEC Filing

Mary Haak-Frendscho, a director at Surrozen, Inc., reported the acquisition of options to purchase 1,333 shares of common stock in a recent SEC Form 4 filing.

Summary

• On June 6, 2024, Mary Haak-Frendscho, a director of Surrozen, Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of options to purchase 1,333 shares of Surrozen's common stock.
• The options were granted on June 5, 2024, with an exercise price of $11.
• The options vest and become exercisable on the anniversary of the grant date, contingent upon continuous service as a director, and expire on June 5, 2034.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The acquisition of options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions and provides insight into director compensation and equity ownership. It's common for directors to receive stock options as part of their compensation package.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies, particularly in the biotechnology sector.
• The size of the grant (1,333 shares) would need to be compared to grants made to directors at comparable companies to determine if it is within industry norms.
• Companies like Amgen, Biogen, and Gilead Sciences also grant stock options to their directors as part of their compensation packages.

Key Dates